The observed increase in DB-specific ADCC by FAP-IL-2 in our in vitro experiments was clearly translated into an FAP-IL-2v-dependent improvement in the antitumor effects of DB against aggressively growing GD2-positive NB tumors in vivo. This evidence concerns the gene IL2 and neuroblastoma.